Compare Stocks: KZIA, SERA, CRDF, and YARW

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$1.37	$1.01	$0.76 ▼ $3.31	$106.58M	1.46	911,554 shs	476,009 shs
KZIA Novogen	$10.65 +2.5%	$12.80	$4.86 ▼ $17.40	$134.75M	2.14	366,685 shs	193,451 shs
SERA Sera Prognostics	$2.12 +1.4%	$2.05	$1.56 ▼ $3.95	$82.25M	0.98	26,134 shs	17,003 shs
YARW Yarrow Bioscience	$28.30 -3.4%	$0.00	$14.75 ▼ $46.95	$78.20M	2.01	131,837 shs	135,986 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	0.00%	+13.22%	+55.66%	+5.38%	-33.17%
KZIA Novogen	0.00%	-7.15%	-22.46%	-25.79%	+33.89%
SERA Sera Prognostics	0.00%	+2.96%	-2.34%	+12.97%	-36.67%
YARW Yarrow Bioscience	0.00%	+8.44%	-19.58%	+2,928,999,900.00%	+2,928,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$1.37	$1.01	$0.76 ▼ $3.31	$106.58M	1.46	911,554 shs	476,009 shs
KZIA Novogen	$10.65 +2.5%	$12.80	$4.86 ▼ $17.40	$134.75M	2.14	366,685 shs	193,451 shs
SERA Sera Prognostics	$2.12 +1.4%	$2.05	$1.56 ▼ $3.95	$82.25M	0.98	26,134 shs	17,003 shs
YARW Yarrow Bioscience	$28.30 -3.4%	$0.00	$14.75 ▼ $46.95	$78.20M	2.01	131,837 shs	135,986 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	0.00%	+13.22%	+55.66%	+5.38%	-33.17%
KZIA Novogen	0.00%	-7.15%	-22.46%	-25.79%	+33.89%
SERA Sera Prognostics	0.00%	+2.96%	-2.34%	+12.97%	-36.67%
YARW Yarrow Bioscience	0.00%	+8.44%	-19.58%	+2,928,999,900.00%	+2,928,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.29	Hold	$7.50	447.45% Upside
KZIA Novogen	2.71	Moderate Buy	$27.33	156.65% Upside
SERA Sera Prognostics	2.67	Moderate Buy	$5.50	159.43% Upside
YARW Yarrow Bioscience	2.33	Hold	$58.00	104.95% Upside

Current Analyst Ratings Breakdown

Latest KZIA, SERA, CRDF, and YARW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2026	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy
9/10/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/10/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/4/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $40.00
8/19/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	KZIA Novogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$29.00
8/11/2026	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/5/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	YARW Yarrow Bioscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy	$58.00
7/31/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$590K	180.63	N/A	N/A	$0.67 per share	2.04
KZIA Novogen	$30K	4,604.35	N/A	N/A	($5.34) per share	-1.99
SERA Sera Prognostics	$80K	1,045.43	N/A	N/A	$1.94 per share	1.09
YARW Yarrow Bioscience	$570K	132.56	N/A	N/A	$41.71 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.85M	-$0.60	N/A	N/A	N/A	-7,885.43%	-103.10%	-75.52%	11/5/2026 (Estimated)
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	-$31.93M	-$0.67	N/A	N/A	N/A	-47,475.72%	-46.71%	-34.06%	11/12/2026 (Estimated)
YARW Yarrow Bioscience	-$26.48M	-$14.64	N/A	N/A	N/A	-4,726.21%	-84.40%	-77.68%	N/A

Latest KZIA, SERA, CRDF, and YARW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	YARW Yarrow Bioscience	-$0.18	-$3.51	-$3.33	-$3.51	$0.20 million	$0.10 million
8/12/2026	Q2 2026	SERA Sera Prognostics	-$0.1542	-$0.18	-$0.0258	-$0.18	$0.07 million	$0.03 million
8/11/2026	Q2 2026	CRDF Cardiff Oncology	-$0.1196	-$0.14	-$0.0204	-$0.14	$0.06 million	$0.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	N/A	N/A	N/A	N/A	N/A
YARW Yarrow Bioscience	N/A	N/A	N/A	N/A	N/A

Latest KZIA, SERA, CRDF, and YARW Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/10/2026	YARW Yarrow Bioscience	special	$19.00			7/22/2026	7/23/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	3.30	3.30
KZIA Novogen	N/A	2.87	N/A
SERA Sera Prognostics	N/A	1.98	1.98
YARW Yarrow Bioscience	N/A	15.26	15.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
KZIA Novogen	30.89%
SERA Sera Prognostics	54.64%
YARW Yarrow Bioscience	83.78%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	8.80%
KZIA Novogen	1.00%
SERA Sera Prognostics	11.30%
YARW Yarrow Bioscience	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	31	77.79 million	70.95 million	Optionable
KZIA Novogen	6	12.97 million	12.84 million	No Data
SERA Sera Prognostics	72	39.45 million	34.99 million	Optionable
YARW Yarrow Bioscience	30	2.67 million	2.59 million	N/A

KZIA, SERA, CRDF, and YARW Headlines

Recent News About These Companies

Yarrow Bioscience Inc YARW

September 15, 2026 | morningstar.comM

Yarrow Bioscience Closes $172.5 Million Public Offering

September 14, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

September 14, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Underwritten Equity Offering Agreement

September 14, 2026 | tipranks.com

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

September 14, 2026 | businesswire.com

Yarrow Bioscience Details Pricing for $150 Million Public Offering of Common Stock

September 14, 2026 | mobile.visionmonday.comM

Yarrow Bioscience Stock Falls 7% On Pricing Of $150 Mln Public Offering

September 13, 2026 | rttnews.com

Short Interest in Yarrow Bioscience (NASDAQ:YARW) Rises By 190.8%

September 13, 2026 | marketbeat.com

Yarrow Bioscience prices $150M public offering of common stock at $26 per share

September 11, 2026 | msn.com

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

September 10, 2026 | businesswire.com

Yarrow Bioscience Launches Public Offering of Common Stock

September 10, 2026 | finance.yahoo.com

Yarrow Bioscience Updates Strategy for Thyroid Autoimmune Pipeline

September 10, 2026 | tipranks.com

Yarrow Bioscience Announces Proposed Underwritten Public Offering

September 10, 2026 | businesswire.com

BlackRock Inc. Takes Position in Yarrow Bioscience $YARW

September 10, 2026 | marketbeat.com

40,697 Shares in Yarrow Bioscience $YARW Purchased by Two Sigma Securities LLC

September 7, 2026 | marketbeat.com

Yarrow Bioscience’s YB-101 Trial Targets Graves’ Disease, Raising New Investor Interest

September 4, 2026 | tipranks.com

Analyst Maintains Buy on Yarrow Bioscience, Sees Attractive Risk-Reward with Unchanged $56 Price Target

August 13, 2026 | tipranks.com

Yarrow Bioscience Alters Capital Structure With Warrant Exchange

July 30, 2026 | tipranks.com

Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

July 29, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves ...

July 27, 2026 | finance.yahoo.com

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

July 23, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA, SERA, CRDF, and YARW Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$1.37 0.00 (0.00%)

As of 04:00 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Novogen NASDAQ:KZIA

$10.65 +0.26 (+2.50%)

As of 04:00 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Sera Prognostics NASDAQ:SERA

$2.12 +0.03 (+1.44%)

As of 04:00 PM Eastern

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Yarrow Bioscience NASDAQ:YARW

$28.30 -0.99 (-3.38%)

As of 04:00 PM Eastern

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZIA, SERA, CRDF, and YARW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZIA, SERA, CRDF, and YARW Earnings

Compare Dividends

Latest KZIA, SERA, CRDF, and YARW Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZIA, SERA, CRDF, and YARW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA, SERA, CRDF, and YARW Company Descriptions

Cardiff Oncology NASDAQ:CRDF

Novogen NASDAQ:KZIA

Sera Prognostics NASDAQ:SERA

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZIA, SERA, CRDF, and YARW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZIA, SERA, CRDF, and YARW Earnings

Compare Dividends

Latest KZIA, SERA, CRDF, and YARW Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZIA, SERA, CRDF, and YARW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA, SERA, CRDF, and YARW Company Descriptions

Cardiff Oncology NASDAQ:CRDF

Novogen NASDAQ:KZIA

Sera Prognostics NASDAQ:SERA

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools